AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2017
Dec 8, 2017
33422_dirs_2017-12-08_a2d1aed8-a4be-4a05-8737-056a3ab86169.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2017-12-07
Reporting Person: FREEMAN KEVIN D (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-12-07 | Common Stock | P | 8000 | $1.6256 | Acquired | 8000 | Indirect |
| 2017-12-07 | Common Stock | P | 400 | $1.6433 | Acquired | 28043 | Direct |
More from GALECTIN THERAPEUTICS INC
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Mar 31
Regulatory Filings
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Regulatory Filings
2026
Mar 17
Director's Dealing
2026
Feb 9
Regulatory Filings
2026
Jan 21